A Randomized, Double-blind, Placebo- and Active-controlled, 4-period, Crossover Study to Investigate Effects of Elinzanetant on Simulated Driving Performance and Cognitive Function in Healthy Women

Researchers are looking for a better way to treat vasomotor symptoms (VMS), also known as hot flashes.
Hot flashes are intense and sudden feelings of heat along with sweating and reddening of the skin. These are common for women going through the menopause but can also occur in men. Such symptoms are called VMS and are caused by changes in sex hormone levels.
The study treatment, elinzanetant, is being tested for the treatment of VMS in both men and women. It works by blocking the activity of a substance called neurokinin, which is thought to play a role in starting hot flashes.
Elinzanetant may cause lasting effects like sleepiness and tiredness. Such effects may make driving unsafe.
The main purpose of this study is to learn how elinzanetant affects the ability to drive the next day in healthy women.
For this, researchers will study participants' ability to keep a stable position within their lane while driving on a straight road on a computer-based driving test (also known as a driving simulator).
In this study, participants will take 2 different doses of elinzanetant, another drug called zopiclone, and matching placebos to these drugs.
Zopiclone helps treat sleeping problems. A placebo looks like a study drug but does not have any medicine in it.
Participants will take elinzanetant, zopiclone, and their matching placebos by mouth.
This study will have 4 treatment periods with each period lasting 6 days. In each period, participants will receive one of the following treatments in an order assigned to them randomly (by chance):
dose A of elinzanetant and a zopiclone placebo
dose B of elinzanetant and a zopiclone placebo
zopiclone 7.5 milligrams (mg) and elinzanetant placebo
elinzanetant placebo and zopiclone placebo
Each participant will be in the study for around 15 weeks with up to 6 visits to the study site.
Participants will visit the study site:
once before the treatment starts, so the study doctors and their team can check on their health and confirm if the participant can join the study
once in each of the 4 treatment periods for a 6-day stay at the study site with a gap of 14 days between each period. During each stay, they will take the assigned treatment from Days 1 to 5 and the driving test on Days 2 and 6
once, 2 to 3 days after their last treatment so the study doctors and their team can check on their health
During the study, the doctors and their study team will:
check participants' health by performing tests such as blood and urine tests, and checking heart health using an electrocardiogram (ECG)
check the participants' ability to drive and their brain function and level of sleepiness using different tests including a driving simulator test
check the level of the study drugs in participants' blood
ask the participants questions about how they are feeling and what adverse events they are having.
An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective of whether they think they are related to the study treatment or not.

Start Date08 Jan 2024

Sponsor / Collaborator

Bayer AG

NCT05819710

/ CompletedPhase 1

A Study to Investigate the Next-day Residual Effects of TS-142 in Healthy Elderly Subjects

This is a study to investigate the next-day residual effects of a single bedtime dosing of 5 mg and 10 mg of TS-142 in Japanese healthy elderly participants in double-blind manner.

Start Date15 May 2023

Sponsor / Collaborator

Taisho Pharmaceutical Co., Ltd.

100 Clinical Results associated with Zopiclone

100 Translational Medicine associated with Zopiclone

100 Patents (Medical) associated with Zopiclone

2,175

Literatures (Medical) associated with Zopiclone

01 Jun 2025·CLINICA CHIMICA ACTA

Advances in Z-drug detection

Review

Author: Kul, Aykut ; Sagirli, Olcay ; Al, Selen

The use of Z-drugs (zolpidem, zaleplon, zopiclone, and eszopiclone) has increased in recent years, leading to a growing need for analytical methods to accurately and reliably detect these compounds in biological samples. This review comprehensively presents the latest developments in the analysis of Z-drugs in biological samples, examining methods such as LC-MS/MS, GC-MS/MS, and HPLC. These methods have been thoroughly evaluated in biological matrices (such as blood, plasma, serum, urine, and hair), with particular focus on characteristics like sample preparation technique, calibration range, LLOQ, analysis time, mobile phase, and column. Recent studies have shown that these methods are effective in routine toxicological analysis and forensic detection of drug abuse. This review aims to provide a valuable resource for researchers and practitioners involved in the detection and analysis of Z-drugs, contributing to a better understanding and management of both therapeutic and illicit use of these compounds.

01 Apr 2025·International Journal of Laboratory Hematology

Zopiclone Overdose Is an Important and Under‐Recognized Cause of Drug‐Induced Oxidative Hemolysis: A Case Series Identified by Heinz Body Test Request

Letter

Author: Law, Winnie Yim Fong ; Lam, Wing Kit ; Yip, Sze Fai

01 Apr 2025·SLEEP MEDICINE

Clinical practice guidelines for switching or deprescribing hypnotic medications for chronic insomnia: Results of European neuropsychopharmacology and sleep expert's consensus group

Review

Author: Serafini, Gianluca ; Dell' Osso, Bernardo M ; Geoffroy, Pierre A ; Maruani, Julia ; Balestrieri, Matteo ; Brugnoli, Roberto ; Ferini-Strambi, Luigi ; Martinotti, Giovanni ; Liguori, Claudio ; Di Nicola, Marco ; Mauries, Sibylle ; Palagini, Laura ; Mencacci, Claudio ; Maina, Giuseppe

INTRODUCTION:

Current guidelines recommend cognitive behavioural therapy for insomnia (CBT-I) as the first-line treatment for chronic insomnia. Pharmacological recommendations by European guidelines for the treatment of insomnia disorder include positive GABAergic modulators such as short and medium acting benzodiazepines and "Z-drugs" (eszopiclone, zaleplon, zolpidem, zopiclone), dual orexin receptor antagonists (DORAs; daridorexant), melatonin receptor agonists (melatonin 2 mg prolonged release - PR). Given the chronic nature of insomnia, the presence of non-responders to some treatments it is often necessary switching between various therapeutic approaches and medications. However, clear guidance regarding safe and effective protocols for switching these medications currently lacks in Europe.

METHOD:

To address this gap, we used the RAND/UCLA Appropriateness to evaluate the appropriateness of procedures for switching medications prescribed for insomnia disorder. Following a systematic review of the literature conducted in accordance with the PRISMA guidelines, we then formulated some recommendations.

RESULTS:

Twenty-one papers were selected.

CONCLUSIONS:

Discontinuation of Hypnotic Benzodiazepines and Z-drugs should be gradual, with dose reductions of 10-25 % each week. Multi-component CBT-I, daridorexant, eszopiclone, and melatonin 2 mg PR were shown to facilitate the gradual discontinuation of hypnotic benzodiazepines/Z-drugs within a cross-tapered program, which can be delayed when necessary. Finally, daridorexant and melatonin 2 mg PR do not require special switching or deprescribing protocols. Several sedative-hypnotic dosage reduction algorithms are proposed in this work for clinical use in real world settings.

News (Medical) associated with Zopiclone

04 Apr 2023

·www.biospace.com

Idorsia Files Petition with the Drug Enforcement Administration (DEA) Urging Them to De-Schedule Dual Orexin Receptor Antagonist Class of Insomnia Medications

RADNOR, Pa., April 4, 2023 /PRNewswire/ -- Yesterday, a Citizen Petition (CP) was filed on behalf of Idorsia Pharmaceuticals (SIX: IDIA), urging the Drug Enforcement Administration (DEA) to de-schedule the dual orexin receptor antagonist (DORA) class of chronic insomnia medications based on a review of evidence from available data, including post-marketing surveillance data. The CP to de-schedule the DORA class outlines scientific and medical evidence demonstrating that the DORA class has a negligible abuse pro potential for abuse, lacks non-medical use in the community, lacks physical and psychological dependence, and therefore, should not be a scheduled class under the Controlled Substances Act.1 Chronic insomnia is a sleep disorder when a person has trouble falling or staying asleep. Insomnia impacts approximately 25 million American adults.2 Among the most commonly prescribed medicines that are approved to treat insomnia are benzodiazepines and Z-drugs (including zopiclone, eszopiclone, zaleplon and zolpidem).3 These drugs are only recommended for short-term use with frequent re-evaluation and due to the risk of dependance and misuse and abuse, are scheduled as Schedule IV under the Controlled Substances Act.4 The Schedule IV classification of the DORA class puts them in the same classification as benzodiazepines and Z-drugs; however, the DORA class works differently, blocking signals in the brain that stimulate wakefulness addressing chronic insomnia without creating dependence and with a negligible potential of abuse. 1 "Given the rising cases of substance abuse disorder with certain prescription medications in the United States, I'm pleased to see data from the DORA class, which shows the negligible abuse potential of DORAs when treating insomnia," said Vaughn McCall, MD, Professor and Case Distinguished Chair of the Department of Psychiatry and Health Behavior at Augusta University. "I am hopeful that the DEA will consider de-scheduling the DORA class as it is critical in preventing the overuse of other medications, which may be abused or misused, to treat insomnia." The CP requests that the DEA Administrator initiate a rulemaking proceeding to remove the DORA class medications from scheduling under the Controlled Substances Act (CSA) based on the following three points: Eight years of post-marketing surveillance data suggests that the DORA class has an insignificant risk of abuse pro potential for abuse, lack of non-medical use in the community; and similar lack of physical or psychological dependence1. Based on major federal surveillance systems including FDA's Adverse Events Reporting System (FAERS) the rates of abuse and dependence-related reports, serious adverse events (AEs), and AEs requiring hospitalization associated with the DORA class are extremely low in incidence and substantially lower than rates for Schedule IV benzodiazepines and related drugs, including those sometimes referred to as "Z-drugs" (namely zopiclone, eszopiclone, zaleplon and zolpidem)1. A re-analysis of the Eight Factors of the Controlled Substances Act (a required step in the scheduling process) supports removal of the DORA class from scheduling under the CSA1. "Idorsia is asking the DEA to de-schedule the DORA class as part of our continued commitment to treating insomnia." said Jean-Paul Clozel, MD, Chief Executive Officer of Idorsia. "As there is significantly more data and evidence on the DORA class today than when these drugs were first approved in 2014, we believe that the DEA should reconsider its decision to schedule these drugs, considering they have negligible abuse profiles and potential for abuse. Access to the DORA class of medicines for insomnia should not be limited by the constraints put in place to manage and restrict the use of scheduled drugs or controlled substances." DORAs block the activity of orexin, they "turn down" overactive wakefulness pathways, in contrast to insomnia treatments which act via general CNS sedation. DORAs specifically target the orexin system by competitively binding and antagonizing both orexin receptors, thereby reversibly blocking the activity of orexin. Blocking orexin receptors reduces the downstream activity of the wake-promoting neurotransmitters that are overactive in insomnia. As a result, orexin receptor antagonism targets the fundamental mechanism of insomnia and does not activate dopamine neurons, thus representing much lower risks of abuse, dependence, and overdose than conventional Schedule IV drugs used to treat insomnia. A Citizen Petition can be filed to ask that a governing agency, like the DEA or US Food and Drug Administration, take or refrain from taking a particular action. Any person may Citizen Petition, and any person may comment on a petition that has been Idorsia cannot predict when or if the DEA will respond to or otherwise take any action concerning the Citizen Petition To view the petition, click here. Notes to the editor About Insomnia According to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5®), insomnia is defined as a combination of difficulty obtaining sufficient sleep and dissatisfaction with sleep combined with a significant negative impact on daytime functioning. Chronic insomnia is defined as difficulty initiating and/or maintaining sleep on at least three nights per week for at least three months, despite adequate opportunity to sleep. Insomnia is a condition of overactive brain activity during sleep, and studies have shown that areas of the brain associated with wakefulness remain more active during sleep in patients with insomnia. Insomnia is the most common sleep disorder, affecting more than 25 million adults in the US.2 Poor quality or insufficient sleep can affect many aspects of the daily lives of people with trouble sleeping including the ability to concentrate, mood and energy levels.4 In the long-term, insomnia is associated with numerous serious health conditions, such as psychiatric disorders, cardiovascular disease, type 2 diabetes, substance abuse and dementia.7,8,9 References EXHIBIT B (statement of grounds) - Petition to Reschedule QUVIVIQ (daridorexant) REVISED DRAFT 3.25.23 Bhaskar S, Hemavathy D, Prasad S. Prevalence of chronic insomnia in adult patients and its correlation with medical comorbidities. J Family Med Prim Care. 2016;5(4):780-784. doi:10.4103/2249-4863.201153 Bertisch, S. M., Herzig, S. J., Winkelman, J. W., & Buettner, C. (2014). National use of prescription medications for insomnia: NHANES 1999-2010. Sleep, 37(2), 343–349. Sateia, M. J., Buysse, D., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017). 0395 clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: An American Academy of Sleep Medicine Clinical Practice guideline. Sleep, 40(suppl_1). U.S. Department of Health and Human Services. (2023, March 8). Drug overdose death rates. National Institutes of Health. Retrieved March 15, 2023, from Drug Overdose Death Rates | National Institute on Drug Abuse (NIDA) (nih.gov) Ustinov Y, Lichstein KL, Wal GS, Taylor DJ, Riedel BW, Bush AJ. Association between report of insomnia and daytime functioning. Sleep Med. 2010 Jan;11(1):65-8. doi: 10.1016/j.sleep.2009.07.009. Epub 2009 Sep 23. 4. Olfson M, Wall M, Liu SM, Morin CM, Blanco C. Insomnia and Impaired Quality of Life in the United States. J Clin Psychiatry. 2018 Sep 11;79(5):17m12020. doi: 10.4088/JCP.17m12020. 5. Doghramji K. The epidemiology and diagnosis of insomnia. Am J Manag Care. 2006 May;12(8 Suppl): S214-20. PMID: 16686591. 6. de Almondes KM, Costa MV, Malloy-Diniz LF, Diniz BS. Insomnia and risk of dementia in older adults: Systematic review and meta-analysis. J Psychiatr Res. 2016 Jun;77:109-15. doi: 10.1016/j.jpsychires.2016.02.021. Epub 2016 Mar 8. PMID: 27017287. About Idorsia US Idorsia US, an affiliate of Idorsia, is reaching out for more – we have more ideas, we see more opportunities, and we want to help more patients. To achieve this, we will help develop Idorsia into a leading biopharmaceutical company, with a strong scientific core. With commercial operations based outside of Philadelphia, PA, one of densest communities of life sciences talent in the world, we are helping to realize the company's ambition of bringing innovative medicines from bench to bedside. Our goal is to build a commercial footprint that will deliver Idorsia's deep pipeline of products from its R&D engine to the US market – with the potential to change the lives of many patients. About Idorsia Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, state-of-the-art facilities, and a strong balance sheet – the ideal constellation to translate R&D efforts into business success. Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 1'000 highly qualified specialists dedicated to realizing our ambitious targets. For further information, please contact US Media Christopher Clark Senior Director, US Head of Communications Idorsia Pharmaceuticals US, 100 Matsonford Road, Radnor, PA 19087 +1 (215) 421 4887 christopher.clark@idorsia.com Global Investors & Media Andrew C. Weiss Senior Vice President, Head of Investor Relations & Corporate Communications Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil +41 58 844 10 10 investor.relations@idorsia.com media.relations@idorsia.com The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Company Codes: Swiss:IDIA

30 Jan 2023

·www.businesswire.com

Sleep Disorder Treatment Drugs Markets in China 2023: Demand to Grow by 5% Annually Through 2032 - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Sleep Disorder Treatment Drugs Markets in China" report has been added to ResearchAndMarkets.com's offering. China's demand for Sleep Disorder Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2012, 2017 and 2022) and long-term forecasts through 2027 and 2032 are presented. Major producers in China are profiled. The primary and secondary research is done in China in order to access up-to-date government regulations, market information and industry data. Data were collected from the Chinese government publications, Chinese language newspapers and magazines, industry associations, local governments' industry bureaus, industry publications, and our in-house databases. Interviews are conducted with Chinese industry experts, university professors, and producers in China. Economic models and quantitative methods are applied in this report to project market demand and industry trends. Metric system is used and values are presented in either Yuan (RMB, current price) and/or US dollars. Our market research reports provide hard-to-find market data and analyses. Today, China has the largest market in the world. Tremendous fast-growing markets for imports and business opportunities for companies around the world. If you want to expand your business or sell your products in China, our research reports provide the insights and projections into Chinese markets necessary for you to do so. Key Topics Covered: I. INTRODUCTION Report Scope and Methodology Executive Summary II. BUSINESS ENVIRONMENT Economic Outlook Key Economic Indicators Industrial Output Population and Labor Foreign Investment Foreign Trade Financial and Tax Regulations Banking System and Regulations Foreign Exchange Taxes, Tariff and Custom Duties III. SLEEP DISORDER TREATMENT DRUGS INDUSTRY ASSESSMENTS Sleep Disorder Treatment Drugs Industry Structure Market Size Market Growth Driver Sleep Disorder Treatment Drugs Sales Volume Major Producer Facility Locations and Sales Volume Market Share of Key Producers Labor Cost Potential Entrants Major Distributors Major Foreign Investments Technology Development IV. SLEEP DISORDER TREATMENT DRUGS PRODUCTION AND DEMAND Overview Sales Volume of Sleep Disorder Treatment Drugs by Region Sleep Disorder Treatment Drugs Sales Volume Western Sleep Disorder Treatment Drugs Sales Volume Barbiturates Phenobarbital Secobarbital Amobarbital Benzodiazepines Midazolam Estazolam Triazolam Others Non-benzodiazepines Zolpidem Zopiclone Zaleplon Others Chinese Traditional Sleep Disorder Treatment Drugs Sales Volume Acanthopanacis Senticosi Gastrodin Chinese Patent Medicines Sleep Disorder Treatment Drugs Imports and Exports Pricing Trends V. SLEEP DISORDER TREATMENT DRUGS MARKET OUTLOOK Sleep Disorder Treatment Drugs Markets Outlook Government Regulations Health Care Insurance Industry Overview Consumer Spending Trends Northeast North Southeast Central Southwest Northwest Demographic Trends Health Care Industry Trends Hospitals and Hospital Beds VI. MARKETING STRATEGIES China Market Entry Overview China's Distribution System Sleep Disorder Treatment Drugs Distribution Channels Transportation and Freight Infrastructure Communications China's Market Entry Export to China Indirect export Direct Export License and Contract Manufacture Assembling in China Contract Manufacturing Trade Permit Investment Equity Joint Venture Contractual Joint Venture Wholly Foreign-Owned Enterprise VII. SLEEP DISORDER TREATMENT DRUGS PRODUCER DIRECTORY Sleep Disorder Treatment Drugs Producer Profiles and Directory A selection of companies mentioned in this report includes Wusuli River Pharmaceutical Group Wandashan Pharmaceutical Factory For more information about this report visit https://www.researchandmarkets.com/r/irmoip About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

26 Jan 2023

·www.businesswire.com

China Sleep Disorder Treatment Drugs Industry Forecasts 2023: Demand to Grow by 5% Annually Through 2032 - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Sleep Disorder Treatment Drugs Industry Forecasts - China Focus" report has been added to ResearchAndMarkets.com's offering. This study focuses on China's Sleep Disorder Treatment Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of goods and services. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market. Although China has enjoyed the benefits of an expanding market for production and distribution, the industry is suffering from minimal innovation and investment in R&D and new product development. The sector's economies of scale have yet to be achieved. Most domestic manufacturers lack the autonomic intellectual property and financial resources to develop their own brand name products. This new study focuses on industry trends and forecasts with historical data (2012, 2017 and 2022) and long-term forecasts through 2027 and 2032 are presented. The primary and secondary research is done in China in order to access up-to-date government regulations, market information and industry data. Data were collected from the Chinese government publications, Chinese language newspapers and magazines, industry associations, local governments' industry bureaus, industry publications, and our in-house databases. The analyst is one of the leading sources for up-to-date market information and research on the fastest-growing Chinese markets. We have published over 1,500 reports focusing on the Chinese markets, industry forecasts and company profiles. We provide hard-to-find market data and analyses. Our publications are intended to help international marketers identify business opportunities and promote their product sales in the Chinese markets. Key Topics Covered: I. INTRODUCTION Report Scope and Methodology Executive Summary II. BUSINESS ENVIRONMENT Economic Outlook Key Economic Indicators Industrial Output Population and Labor Foreign Investment Foreign Trade Financial and Tax Regulations Banking System and Regulations Foreign Exchange Taxes, Tariff and Custom Duties Market Trends Technology Development Market Development Major Industry Development Regional Development Enterprise Development Labor Market Development III. SLEEP DISORDER TREATMENT DRUGS PRODUCTION AND DEMAND Overview Sales Volume of Sleep Disorder Treatment Drugs by Region Sleep Disorder Treatment Drugs Sales Volume Western Sleep Disorder Treatment Drugs Sales Volume Barbiturates Phenobarbital Secobarbital Amobarbital Benzodiazepines Midazolam Estazolam Triazolam Others Non-benzodiazepines Zolpidem Zopiclone Zaleplon Others Chinese Traditional Sleep Disorder Treatment Drugs Sales Volume Acanthopanacis Senticosi Gastrodin Chinese Patent Medicines Sleep Disorder Treatment Drugs Imports and Exports Pricing Trends For more information about this report visit https://www.researchandmarkets.com/r/njb95-disorder?w=4 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

100 Deals associated with Zopiclone

External Link

KEGG	Wiki	ATC	Drug Bank
D01372	Zopiclone	N05CF01	DB01198

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Sleep Initiation and Maintenance Disorders	Japan	Sanofi KK	31 Mar 1989

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02807922 (Pubmed)	Phase 4	Advanced cancer	41	Zopiclone	irensgqvst(tipacteegi) = wwzcmluulx wbakxbyezm (vzmogaoxbh, 2.3 - 3.8) View more	Positive	19 Dec 2022
				Placebo	irensgqvst(tipacteegi) = kinhxbtsnc wbakxbyezm (vzmogaoxbh, 3.6 - 5.4) View more
ACTRN12617000988358 (Pubmed \| Chest)	Not Applicable	Sleep Apnea, Obstructive	28	High-dose Zopiclone 15mg	ynijihivhg(axhouuqkoz) = owmtnurtpd ouugfvmtpv (iwfdtepzae, -6.6 to 3.5)	-	01 Jul 2020
NCT02732912 (SleepSure, CTgov)	Phase 3	Sleep	206	Zopiclone (Control)	daadrtapii(xzlbrcyypw) = zwejpzrpuy thqshimkax (jqzszbwato, 2.05) View more	-	01 Oct 2019
				Ear plugs+Zopiclone (Eye Mask and Ear Plugs)	daadrtapii(xzlbrcyypw) = qavwnguokg thqshimkax (jqzszbwato, 2.13) View more
ACTRN12617000988358 (WSC2019)	Phase 2	Sleep Apnea, Obstructive \| Sleep Apnea Syndromes	28	Zopiclone 15mg	hchptyubuq(heopwkqowz) = noxpycefxs bdyzxrrpej (vihwudbyiv ) View more	Negative	20 Sep 2019
				Placebo	hchptyubuq(heopwkqowz) = kxlbhnyikh bdyzxrrpej (vihwudbyiv ) View more
WSC2017	Not Applicable	Sleep Initiation and Maintenance Disorders	36	Sleep medication (+)	ejjujswfdv(iakgkrkotf) = pegndvazsd wizlofxxuj (aqvlwgawzd, 8.7) View more	Negative	07 Oct 2017
				Sleep medication (-)	ejjujswfdv(iakgkrkotf) = xhwasleapx wizlofxxuj (aqvlwgawzd, 8.4) View more
ACTRN12614000364673 (Pubmed \| Sleep)	Not Applicable	Sleep Apnea, Obstructive	12	Zopiclone	lqfgermzxi(ziiofhvpce) = vcrszcolxo xtmolyxsmv (wwxpkexrqw ) View more	-	01 Apr 2016
				Placebo	lqfgermzxi(ziiofhvpce) = savaqwyaoo xtmolyxsmv (wwxpkexrqw ) View more
NCT00319215 (Pubmed \| Sleep)	Phase 1	-	30	Ramelteon 8 mg	eobhgchrhf(tksxtyitsc) = csjvposvsr itagfmaner (tmjgipffih )	-	01 Oct 2011
				Zopiclone 7.5 mg	eobhgchrhf(tksxtyitsc) = yaxfiwpeoz itagfmaner (tmjgipffih )
Pubmed	Not Applicable	Sleep Initiation and Maintenance Disorders	-	Sedative hypnotics	sbumljppfi(peicjfspjp) = Adverse events were more common with sedatives than with placebo: adverse cognitive events were 4.78 times more common (95% confidence interval 1.47 to 15.47, P < 0.01); adverse psychomotor events were 2.61 times more common (1.12 to 6.09, P > 0.05), and reports of daytime fatigue were 3.82 times more common (1.88 to 7.80, P < 0.001) in people using any sedative compared with placebo hldufmexqe (xfwvzxafpr )	-	19 Nov 2005

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis